Effects and Interferences of Emicizumab, a Humanized Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Lupus Anticoagulant Assays
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Emicizumab: the hemophilia A game-changer.
Alcedo Andrade P, Mannucci P, Kessler C Haematologica. 2023; 109(5):1334-1347.
PMID: 37916312 PMC: 11063855. DOI: 10.3324/haematol.2022.282099.
References
1.
Tripodi A, Chantarangkul V, Cini M, Devreese K, Dlott J, Giacomello R
. Variability of cut-off values for the detection of lupus anticoagulants: results of an international multicenter multiplatform study. J Thromb Haemost. 2017; 15(6):1180-1190.
DOI: 10.1111/jth.13678.
View
2.
Hoxha A, Banzato A, Ruffatti A, Pengo V
. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun Rev. 2016; 16(2):173-178.
DOI: 10.1016/j.autrev.2016.12.010.
View
3.
Triplett D, Barna L, Unger G
. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost. 1993; 70(5):787-93.
View
4.
Rampersad A, Boylan B, Miller C, Shapiro A
. Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients. Haemophilia. 2018; 24(5):807-814.
PMC: 6345165.
DOI: 10.1111/hae.13565.
View
5.
Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A
. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017; 117(7):1348-1357.
PMC: 6292136.
DOI: 10.1160/TH17-01-0030.
View